NEUROCRINE BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 140.1 USD | +4.81% |
|
+5.34% | +6.32% |
Presenter SpeechChris Shibutani (Analysts)Good morning, and welcome, everybody. The Wednesday,...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntingtonâs disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
Calendar
2024-05-01
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
C+
Sell
Buy
Mean consensus
BUY
Number of Analysts
29
Last Close Price
140.1
USD
Average target price
153.6
USD
Spread / Average Target
+9.61%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +6.32% | 14.09B | |
| -0.49% | 105B | |
| +3.31% | 97.5B | |
| +1.66% | 22.19B | |
| -16.16% | 21.33B | |
| -6.82% | 18.68B | |
| -41.41% | 16.6B | |
| -22.87% | 14.52B | |
| +21.46% | 10.99B | |
| -21.14% | 8.63B |
- Stock Market
- Equities
- NBIX Stock
- News Neurocrine Biosciences, Inc.
- Transcript : Neurocrine Biosciences, Inc. Presents at Goldman Sachs 43rd Annual Global Healthcare Conference, Jun-15-2022 10
